Overview
This is a phase I/II, open-label, multicenter study . During the study, subjects will be evaluated for safety, toxicity, tolerability, PK/PD, immunogenicity, biomarkers, and antitumor activity of HB0045. The phase I study will enroll up to 54 subjects with advanced solid tumors who have progressed on or after standard of care therapy and for whom there is no further treatment available that in the judgement of the patient's physician would be beneficial. One cycle is defined as 21 days.
Description
During the phase I study, the safety and tolerability of HB0045 will be evaluated in patients with advanced solid tumors including understanding of the preliminary efficacy. During this phase of the study, DLTs, MTD and MTD range will be observed which will inform RP2D. Phase I:Approximately 54 patients will receive HB0045 as a monotherapy at escalating doses.One cycle is defined as 3 weeks (21 days).
In the phase II study, the safety and preliminary efficacy of HB0045 at the RP2D will be evaluated in cohorts of patients with pancreatic, colorectal, ovarian cancer and/or other solid tumors.Phase II:During the dose escalation process, expansion cohorts will be conducted based on the preliminary RP2D.A Simon 2-stage design will be utilized with a stopping rule to allow for early termination of a particular cohort at the end of Stage 1 if patients have insufficient responses to HB0045. During Stage 1, 9 evaluable patients will be enrolled in each cohort; if no responses are observed within the cohort, then the cohort will be discontinued. If at least 1 response is observed, 8 additional evaluable patients will be enrolled in the cohort (Stage 2), for a maximum of 17 evaluable patients per cohort.
Eligibility
Inclusion Criteria:
- Male or female, aged ≥ 18 years.
- The subject can understand and willing to sign the ICF and is willing and able to comply with all study procedures.
- Phase I: Patients with histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors (or clinically diagnosed hepatocellular carcinoma) that failed (progressed on or are intolerant of) all standard therapies known to provide clinical benefit; [These solid tumors include but not limited to: pancreatic, colorectal, ovarian, breast, lung, head and neck, prostate, renal cancer, and sarcoma, etc.]
- Phase II: Patients who have had at least one systemic therapy and has progressed, and
might benefit from the study drug in the Investigator's judgment, and have the
following histological types (The types of tumors and the number of treatment lines
may be adjusted based on phase I results and /or SRC discussions):
- Pancreatic cancer cohort: i. Histologically or cytologically confirmed pancreatic ductal adenocarcinoma. ii. Unresectable, locally advanced recurrent or metastatic. b) CRC cohort: i. Histologically or cytologically confirmed colorectal cancer. ii. Molecular typing: non-dMMR/ non-MSI-H colorectal cancer. c) Ovarian cancer cohort: i. Histologically or cytologically confirmed unresectable metastatic ovarian, fallopian tube or peritoneal cancer ii. Epithelial type including high-grade serous cell carcinoma, endometrioid carcinoma or clear cell carcinoma.
iii. No history of ileus (including signs or symptoms of ileus) within 3 months prior
to screening.
iv. Patients who had not received enterostomy within 3 months prior to screening.
v. Have failed (progressed on or are intolerant of) all standard therapies known to
provide clinical benefit; including but not limited to treatment with platinum-based
chemotherapy if platinum-sensitive disease, and treatment with chemotherapy +
bevacizumab if platinum-resistant and have not received prior bevacizumab.
d) Other advanced cancer cohort(s): Tumor specific type that demonstrated partial
response to HB0045 in dose escalation phase.
5. At least one measurable lesion as per RECIST v. 1.1 defined as non-nodal lesions
having at least one dimension with a minimum size of 10 mm in the longest diameter by
CT or MRI scan or ≥15 mm in short axis for nodal lesions. Radiographic disease
assessment at baseline can be performed up to 21 days prior to the first dose.
Note: Tumor lesions situated in a previously irradiated area, or in an area subjected
to other loco-regional therapy, are not considered measurable unless there has been
demonstrated progression in the lesion.
6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
7. Life expectancy ≥12 weeks.
8. Patients with active hepatitis B virus (HBV) without active disease (HBV DNA titer
<1000 cps/mL or 200 IU/mL), or who are cured of hepatitis C virus (HCV) with a
negative HCV RNA test may be enrolled at the investigator's discretion.
9. Patients with known human immunodeficiency virus (HIV) infection and a cluster of
differentiation 4 (CD4) count that is documented to be ≥350 cells/mm3 within 12 months
before study screening, and if HIV-infected patients with a lower CD4+ count
(<350cell/ mm3)，should be eligible only if they have a potentially curable malignancy
or for interventions in a later stage of development that have demonstrated prior
activity with a given cancer.
10. Adequate organ function within 14 days of the first dose as defined by the following
criteria:
1. Hematology i. absolute neutrophil count (ANC) ≥ 1.5×109/L ii. platelets (PLT) ≥
100×109/L iii. hemoglobin (HGB) ≥ 90 g/L Note: The above items require that
patients have not received any blood component or supportive therapy with growth
hormones within two weeks prior to blood sampling.
2. Renal function: Calculated creatinine clearance (CrCL) > 30 mL/min
(Cockroft-Gault Equation)
3. Liver function i. AST and ALT ≤ 2.5×ULN; AST or ALT ≤ 5×ULN if liver metastases
are present ii. Total bilirubin (TBIL) ≤ 1.5×ULN; ≤3 X ULN for patients with
Gilbert's disease
4. Coagulation function i. International normalized ratio (INR) or prothrombin time
(PT)≤ 1.5×ULN (unless the patient is on stable dose of oral anticoagulant) ii.
Activated partial thromboplastin time (APTT)≤ 1.5×ULN
11. Women of childbearing potential must confirm a negative serum pregnancy test within 3
days prior to the initiation of study treatment and begin use of an effective birth
control directly after testing negative for pregnancy; Fertile patients and their
partners must agree to use acceptable contraception for the duration of study drug use
and for 120 days after the last administration of study treatment.
Acceptable contraception Single method i. Intrauterine device (IUD) ii. Vasectomy of a
female subject's male partner iii. Contraceptive rod implanted into the skin Combined
method (requires the use of two of the following) i. Diaphragm with spermicide (cannot
be used in conjunction with cervical cap/spermicide) ii. Cervical cap with spermicide
(nulliparous women only) iii. Contraceptive sponge (nulliparous women only) iv. Male
condom or female condom (cannot be used together) v. Hormonal contraceptive: oral
contraceptive pill (estrogen/progestin pill or progestin -only pill), contraceptive
skin patch, vaginal contraceptive ring, or subcutaneous contraceptive injection.
12. Recovery to Grade 0-1 from adverse events (AEs) related to prior anticancer therapy
except alopecia, < Grade 2 sensory neuropathy, and endocrinopathies controlled with
hormone replacement therapy.
Exclusion Criteria:
1. Concurrent malignancy < 5 years prior to entry other than adequately treated cervical
carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma,
localized prostate cancer, ductal carcinoma in situ of the breast, or < T1 urothelial
carcinoma. Patients with prostate cancer that is under active surveillance are
eligible.
2. Have clinically active central nervous system (CNS) metastases and/or carcinomatous
meningitis. Patients with previously treated brain or meningeal metastases may
participate and be eligible for treatment provided they are stable and asymptomatic.
Patients with asymptomatic brain or meningeal metastasis or patients who are
symptomatically stable after treatment and are on≤ 10 mg/d prednisone or equivalent
are eligible.
3. Cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction
(MI), unstable angina, or New York Heart Association (NYHA) class III or IV heart
failure occurred within 6 months before study admission; QT-interval corrected
according to Fridericia's formula (QTcB) > 480 milliseconds (ms) obtained from three
consecutive ECGs; uncontrolled arrhythmia < 3 months of study entry (judged by the
Investigator). Patients with rate-controlled arrhythmias may be eligible for study
entry at discretion of the Investigator.
4. Active autoimmune disease or history of autoimmune disease requiring systemic therapy
< 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease,
Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that
has not been active in the 2 years prior to study screening are eligible.
5. Patients who have previously received allogeneic stem cell or solid organ
transplantation.
6. History of severe allergic reactions, grade 3-4 allergic reactions to treatment with
another monoclonal antibody or known to be allergic to protein drugs or recombinant
proteins or excipients in HB0045 drug formulation.
7. History of Grade 3-4 immune-related adverse events (irAEs) or irAEs requiring
discontinuation of prior therapies, (except for Grade 3 endocrinopathy that is managed
with hormone replacement therapy).
8. Use of systemic corticosteroids in a dose equivalent to ≥10 mg/day of prednisone or
other immunosuppressive agents < 2 weeks prior to screening; the use of topical,
intraocular, intraarticular, intranasal, or inhaled corticosteroids and systemic
steroids to prevent (e.g., allergy to contrast agents) or treat non-autoimmune
condition (e.g., delayed hypersensitivity caused by exposure to allergens), or short
course (< 5 days) will be allowed.
9. Have received antibiotics lasting over 1 week within 28 days prior to first dose.
10. Have received or will receive a live vaccine within 4 weeks prior to the first dose.
11. Any of the following infections
1. Positive COVID-19 qRT-PCR or rapid screening test during screening; can be
eligible after quarantine (14 days) if COVID-19 test becomes negative.
2. Patients with active tuberculosis (TB) who are receiving anti-TB treatment or who
received anti-TB treatment within 1 year prior to screening.
12. Prior treatment with agents targeting CD73 or A2AR.
13. Anticancer therapy < 5 half-lives or 4 weeks (whichever is shorter) prior to study
entry; palliative radiotherapy to a single area < 2 weeks prior to study screening is
permitted. Measurable lesions cannot be previously irradiated unless they have
demonstrated growth after radiation therapy (RT).
14. Major surgery (except for diagnostic needle biopsy or puncture and drainage or
intravenous catheterization) or chemotherapy/ interventional therapy/radiation
therapy/ablation therapy < 4 weeks prior to the first dose
15. Patients who have participated in any clinical trial of a drug or medical device
within 4 weeks prior to the first dose.
16. Patients whose existing significant clinical abnormalities or laboratory abnormalities
may affect the evaluation of the study drug by the Investigator's judgement.
Psychiatric, psychological, familial condition or geographical location that, in the
judgment of the Investigator, may interfere with the planned staging, treatment and
follow-up and affect patient's compliance or place the patient at high risk from
treatment.
17. Other conditions which would make it inappropriate for the patient to participate as
judged by the investigator.